BioWorld

March 28, 2007

Aerovance Tops Off Series C By Garnering $32M Payout

After raising $28 million almost a year ago in the first tranche of a Series C financing, Aerovance Inc. brought in an additional $32 million in a second tranche, completing the $60 million round. (BioWorld Today) Read More

Frost Leads Three-Way Merger That Includes Acuity, Froptix

Regeneron Rises On Interim VEGF Trap-Eye Data In AMD

BioCryst Eyeing New Direction For Fodosine Following Setback

Regado Ends $23 Million Round;Now Developing Anticoagulant

MediciNova MS Phase II: Missed Endpoint, But Hope Remaining

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...